



Antimicrobial Combination Therapy to Treat Difficult-to-Treat Infections: From Bench to the Bedside

Guest Editors:

Dr. Alessandra Oliva

Department of Public Health and
Infectious Diseases, Sapienza
University of Rome, Rome, Italy

Dr. Erlangga Yusuf

Department of Medical
Microbiology and Infectious
Diseases, Erasmus University
Medical Center, Rotterdam, The
Netherlands

Dr. Alessandra Mularoni

Infectious Disease and Infection
Control Unit, IRCCS-ISMETT,
UPMC, Palermo, Italy

Deadline for manuscript
submissions:

15 August 2024

Message from the Guest Editors

In recent years, the combination of new or already known antimicrobial substances has been exploited to overcome the increasing problem of multidrug resistance. In this setting, definite evidence of the optimal indications of combination therapy or its superiority over monotherapy is still lacking, and represents an area of debate.

Studies are needed to understand whether combination therapy can be used and show satisfactory efficacy. Clinical microbiology studies and susceptibility tests are needed to investigate in vitro synergisms. Pharmacokinetic/pharmacodynamic studies are needed to understand whether the target attainment can be reached. Clearly, clinical studies, either observational or randomized control trials, are needed to investigate the efficacy of combination therapy.

In this Special Issue of *Antibiotics*, we welcome the submission of original research and review articles. Pharmacokinetic/pharmacodynamic studies may also be considered. We welcome fundamental science, animal studies, clinical trials, and observational studies. We are particularly interested in new antibiotics or molecules used to treat multidrug-resistant microorganisms.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)